Content by Lonza

Hugh White from Lonza introduces a nucleic acid separation system designed for modern, efficient research.

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain

In this webinar, Stefanie Müthel and Jessica Fiege will discuss how electroporation using the latest technology boosts cell engineering research by optimizing T cell transfection at scale.

In this webinar, Scott Kelsey, Kevin Grady, and Christopher Hughes will highlight how angiogenesis and vascularized in vitro models accelerate drug development.

Learn how immunotoxicity studies can benefit from optimized macrophage differentiation and polarization.

Learn how visualizing angiogenesis in real time supports drug development.

New methods for deriving macrophages from induced pluripotent stem cells are easier to scale and provide more clinically relevant data.

In this webinar, Ethan Shelkey and Aurita Menezes will highlight key aspects in the design of cell-based assays.

The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex^® Biopark in Visp (CH).

CASGEVY^® is the first cell therapy based on the CRISPR/Cas9 technology, discoverers of which were awarded the Nobel Prize in Chemistry in 2020.

Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

Discover how implementation of next-generation Manufacturing Execution Systems (MES) can be optimized and streamlined to pave the way to faster pharma digitalization.

On 12 November, Lonza will host a free 60-minute webinar during which Nephron Pharmaceuticals will explain its decision to take a paperless approach to batch record management. Nephron will also discuss how its close relationship with Lonza allowed for a rapid implementation of Lonza's MODA-ES™ Electronic Batch Record (EBR) Platform in just nine months, leading to increased operational efficiency and expanded product lines.

·        Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting
· The MODA-ES™ Platform was implemented at Nephron in an aggressive nine-month time frame, improving operational efficiency and enabling a significant product line expansion
·        Full results of the collaboration will be co-presented by Lonza and Nephron at the 2019 ISPE Annual Meeting & Expo in Las Vegas, Nevada

Lonza has introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs. Researchers across pharmaceutical and contract manufacturing organizations can now choose from an extensive range of services, including cell-line expansion and banking, media production, cell isolation, cell characterization, transfection services, and 3-dimensional (3D) cell-culture services.